RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment.

Riccardo Spizzo, David Rushworth, Manrique Guerrero, George A. Calin

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Over the past few years, molecular oncology research has revealed that abnormalities in both protein-coding genes (PCGs) and noncoding RNAs (ncRNAs) can be identified in tumors and that the interplay between PCGs and ncRNAs is causally involved in the initiation, progression, and metastases of human cancers. MicroRNAs (miRNAs), which are among the most studied ncRNAs, are small 19- to 25-nucleotide genes involved in the regulation of PCGs and other ncRNAs. With the recent findings of miRNAs' involvement in cancer, RNA inhibition can be used to treat cancer patients in two ways: (1) by using RNA or DNA molecules as therapeutic drugs against messenger RNA of genes involved in the pathogenesis of cancers and (2) by directly targeting ncRNAs that participate in cancer pathogenesis. In this review, we focus on the possible use of miRNAs or compounds interacting with miRNAs as new therapeutic agents in cancer patients.

Original languageEnglish
JournalClinical Lymphoma and Myeloma
Volume9 Suppl 3
Publication statusPublished - 2009

Fingerprint

MicroRNAs
Untranslated RNA
RNA
Neoplasms
Therapeutics
Small Untranslated RNA
Proteins
Genes
Nucleotides
Neoplasm Metastasis
Messenger RNA
DNA
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment. / Spizzo, Riccardo; Rushworth, David; Guerrero, Manrique; Calin, George A.

In: Clinical Lymphoma and Myeloma, Vol. 9 Suppl 3, 2009.

Research output: Contribution to journalArticle

Spizzo, Riccardo ; Rushworth, David ; Guerrero, Manrique ; Calin, George A. / RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment. In: Clinical Lymphoma and Myeloma. 2009 ; Vol. 9 Suppl 3.
@article{abafb46bfa2147ec865fac56ebab474c,
title = "RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment.",
abstract = "Over the past few years, molecular oncology research has revealed that abnormalities in both protein-coding genes (PCGs) and noncoding RNAs (ncRNAs) can be identified in tumors and that the interplay between PCGs and ncRNAs is causally involved in the initiation, progression, and metastases of human cancers. MicroRNAs (miRNAs), which are among the most studied ncRNAs, are small 19- to 25-nucleotide genes involved in the regulation of PCGs and other ncRNAs. With the recent findings of miRNAs' involvement in cancer, RNA inhibition can be used to treat cancer patients in two ways: (1) by using RNA or DNA molecules as therapeutic drugs against messenger RNA of genes involved in the pathogenesis of cancers and (2) by directly targeting ncRNAs that participate in cancer pathogenesis. In this review, we focus on the possible use of miRNAs or compounds interacting with miRNAs as new therapeutic agents in cancer patients.",
author = "Riccardo Spizzo and David Rushworth and Manrique Guerrero and Calin, {George A.}",
year = "2009",
language = "English",
volume = "9 Suppl 3",
journal = "Clinical Lymphoma and Myeloma",
issn = "1557-9190",
publisher = "Cancer Information Group, LP",

}

TY - JOUR

T1 - RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment.

AU - Spizzo, Riccardo

AU - Rushworth, David

AU - Guerrero, Manrique

AU - Calin, George A.

PY - 2009

Y1 - 2009

N2 - Over the past few years, molecular oncology research has revealed that abnormalities in both protein-coding genes (PCGs) and noncoding RNAs (ncRNAs) can be identified in tumors and that the interplay between PCGs and ncRNAs is causally involved in the initiation, progression, and metastases of human cancers. MicroRNAs (miRNAs), which are among the most studied ncRNAs, are small 19- to 25-nucleotide genes involved in the regulation of PCGs and other ncRNAs. With the recent findings of miRNAs' involvement in cancer, RNA inhibition can be used to treat cancer patients in two ways: (1) by using RNA or DNA molecules as therapeutic drugs against messenger RNA of genes involved in the pathogenesis of cancers and (2) by directly targeting ncRNAs that participate in cancer pathogenesis. In this review, we focus on the possible use of miRNAs or compounds interacting with miRNAs as new therapeutic agents in cancer patients.

AB - Over the past few years, molecular oncology research has revealed that abnormalities in both protein-coding genes (PCGs) and noncoding RNAs (ncRNAs) can be identified in tumors and that the interplay between PCGs and ncRNAs is causally involved in the initiation, progression, and metastases of human cancers. MicroRNAs (miRNAs), which are among the most studied ncRNAs, are small 19- to 25-nucleotide genes involved in the regulation of PCGs and other ncRNAs. With the recent findings of miRNAs' involvement in cancer, RNA inhibition can be used to treat cancer patients in two ways: (1) by using RNA or DNA molecules as therapeutic drugs against messenger RNA of genes involved in the pathogenesis of cancers and (2) by directly targeting ncRNAs that participate in cancer pathogenesis. In this review, we focus on the possible use of miRNAs or compounds interacting with miRNAs as new therapeutic agents in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=74049101743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049101743&partnerID=8YFLogxK

M3 - Article

C2 - 19778859

AN - SCOPUS:74049101743

VL - 9 Suppl 3

JO - Clinical Lymphoma and Myeloma

JF - Clinical Lymphoma and Myeloma

SN - 1557-9190

ER -